MUTEINS OF HUMAN LIPOCALIN 2 WITH AFFINITY FOR GLYPICAN-3 (GPC3)
1 Assignment
0 Petitions
Accused Products
Abstract
The present disclosure relates to novel, specific-binding therapeutic and/or diagnostic proteins directed against Glypican-3 (GPC3), which proteins preferably are muteins of a lipocalin protein, more preferably of lipocalin 2 (Lcn2 or NGAL). Present disclosure also relates to nucleic acid molecules encoding such proteins and to methods for generation and use of such proteins and nucleic acid molecules. Accordingly, present disclosure also is directed to pharmaceutical and/or diagnostic compositions comprising such lipocalin proteins, including uses of these proteins.
-
Citations
35 Claims
-
1-15. -15. (canceled)
-
16. A nucleic acid molecule comprising a nucleotide sequence encoding a human neutrophil gelatinase-associated lipocalin (hNGAL) mutein capable of binding glypican-3 (GPC3) with detectable affinity, wherein the mutein comprises a mutated amino acid residue at the sequence position 65 in comparison with the linear polypeptide sequence of mature hNGAL (SEQ ID NO:
- 1), and wherein the mutein has at least 85% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs;
5-16. - View Dependent Claims (17, 18, 19, 20, 21, 22, 23, 24, 25, 26)
- 1), and wherein the mutein has at least 85% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs;
-
27. An hNGAL mutein capable of binding GPC3 with detectable affinity, wherein the mutein comprises a mutated amino acid residue at the sequence position 65 in comparison with the linear polypeptide sequence of mature hNGAL (SEQ ID NO:
- 1), and wherein the mutein has at least 85% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs;
5-16. - View Dependent Claims (28, 29, 30, 31, 32, 33, 34, 35)
- 1), and wherein the mutein has at least 85% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs;
Specification
-
- Resources
Litigation Campaign Assessment
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
-
Current AssigneePieris Pharmaceuticals GmbH (Pieris Pharmaceuticals, Inc.)
-
Original AssigneePieris Pharmaceuticals GmbH (Pieris Pharmaceuticals, Inc.)
-
InventorsHinner, Marlon, Allersdorfer, Andrea, Bel Aiba, Rachida Siham, Aloe, Michaela, Wiedenmann, Alexander, Matschiner, Gabriele, Huelsmeyer, Martin
-
Granted Patent
-
Time in Patent OfficeDays
-
Field of Search
-
US Class Current
-
CPC Class CodesA61K 38/00 Medicinal preparations cont...A61K 38/02 Peptides of undefined numbe...A61P 1/16 for liver or gallbladder di...A61P 17/00 Drugs for dermatological di...A61P 35/00 Antineoplastic agentsC07K 14/4725 Proteoglycans, e.g. aggreccanC12N 15/102 Mutagenizing nucleic acidsG01N 33/50 Chemical analysis of biolog...
